Long-term thymopentin treatment in systemic scleroderma.
A study was carried out to investigate whether thymopentin treatment is capable of inducing changes in the immunological status of patients with systemic scleroderma and to compare any such changes with modifications in clinical condition. Nine patients were given thymopentin, 1 ml in 10 ml saline solution, by slow intravenous infusion 3-times weekly for 5 weeks (cycle). The cycles were repeated at 3-month intervals. Treatment duration ranged from 1 to 5 years. Blood samples were drawn at the beginning and at the end of each cycle and the patients' lymphocytic sub-populations were examined. A control group of 9 comparable healthy subjects were similarly tested. Data analysis showed that a statistically significant decrease of CD16+ and CD25+ lymphocytes compared to pretreatment was already apparent at the end of the first thymopentin treatment cycle. An improvement was found in the clinical condition of 7 of the 9 patients at the end of the follow-up period with a significant correction of unbalanced lymphocytic subsets.
Danese
C
C
Clinica Medica II, Università degli Studi di Roma La Sapienza, Italy.
Zavattaro
E
E
Calisi
L
L
Marcianò
F
F
Perego
M A
MA
D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D005260:Female; D006801:Humans; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000276:immunology; D016305:Thymopentin / Q000008:administration & dosage / Q000627:therapeutic use*
D000974:Antibodies, Antinuclear; D016305:Thymopentin